Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 1

2(28.6%)

Phase 3

1(14.3%)

7Total

Phase 2(4)

Phase 1(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00068172Phase 1Completed

Study of PI-88 in Patients With Advanced Melanoma

Role: lead

NCT00103389Phase 2Completed

Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Role: lead

NCT00097851Phase 2Completed

Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

Role: lead

NCT00073892Phase 1Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Role: lead

NCT01402908Phase 3Terminated

A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

Role: lead

NCT00247728Phase 2Completed

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Role: lead

NCT00130442Phase 2Completed

Trial of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

Role: lead

All 7 trials loaded